PALISADE THERAPEUTICS
Palisade Therapeutics develops therapeutics-based products for the treatment of neurological diseases.
PALISADE THERAPEUTICS
Industry:
Biotechnology Health Care Medical Therapeutics
Founded:
2015-01-01
Address:
Berkeley, California, United States
Country:
United States
Website Url:
http://www.palisadetherapeutics.com
Total Employee:
1+
Status:
Active
Total Funding:
0
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible Domain Not Resolving GoDaddy DNS Google Google Cloud OpenResty Google Adsense Google Cloud Global Multi-Region AdBlock Acceptable Ads
Similar Organizations
Galenea
Galenea is engaged in developing therapeutics for central nervous system diseases.
Gloriana Therapeutics
Gloriana Therapeutics develops first-in-class transformational therapeutics for neurological disorders.
TNeuroPharma
TNeuroPharma develops a therapeutic-based technology focusing on the T-cell contribution in tracking and treating neurodegenerative disease.
Current Employees Featured
Founder
Investors List
SkyDeck Berkeley
SkyDeck Berkeley investment in Non Equity Assistance - Palisade Therapeutics
Official Site Inspections
http://www.palisadetherapeutics.com
Unable to get host informations!!!
More informations about "Palisade Therapeutics"
Palisade Bio | Advancing Next-Generation Precision …
©2024 Palisade Bio. All rights reserved.See details»
About Us – Overview - Palisade Bio
Our lead program, PALI-2108, is a microbiota-activated PDE4 inhibitor prodrug in development for the treatment of moderate-to-severe ulcerative colitis.See details»
Palisade Bio | Advancing Next-Generation Precision Therapies
Sep 16, 2024 Palisade Bio Launches New Corporate Branding and Reiterates Commitment to Advancing Next-Generation Precision Therapies. Sep 16, 2024See details»
Palisade Therapeutics Company Profile 2024: Valuation, Funding ...
Palisade Therapeutics General Information Description. Provider of therapeutics based products intended to treat progressive neurological diseases. The company's products treat with a two …See details»
Palisade Therapeutics - Drug pipelines, Patents, Clinical trials
Explore Palisade Therapeutics with its drug pipeline, therapeutic area, technology platform, 3 news.See details»
Palisade Bio, Inc. (PALI) Company Profile & Overview - Stock Analysis
Ticker Symbol: PALI: Exchange: NASDAQ: Fiscal Year: January - December: Reporting Currency: USD: CIK Code: 0001357459: CUSIP Number: 696389105: ISIN Number: …See details»
Palisade Therapeutics - VentureRadar
Provider of therapeutics based products intended to treat progressive neurological diseases. The company’s therapeutics based products treat with a... ... Find out ...See details»
Palisade Bio Launches New Corporate Website and Reiterates …
Aug 1, 2022 New website aligns with company’s mission to become a global leader in addressing diseases linked to intestinal barrier disruption and establishing new standards of …See details»
Investors & News - Palisade Bio
5 days ago Palisade Bio is a biopharmaceutical company dedicated to advancing next-generation precision therapies for immune, inflammatory, and fibrotic diseases.See details»
Palisade Bio Announces Positive Preclinical Data of Lead Program …
Carlsbad, CA, Jan. 29, 2024 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade” or the “Company”), a biopharmaceutical company focused on developing novel …See details»
Palisade Bio Launches New Corporate Branding and Reiterates …
Carlsbad, CA, Sept. 16, 2024 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade,” “Palisade Bio” or the “Company”), a biopharmaceutical company focused on …See details»
Palisade Bio Cleared by Health Canada to Commence Phase 1 …
Oct 10, 2024 –Company has received a No Objection Letter from Health Canada in response to submission of its Phase 1 Clinical Trial Application (CTA) – The study is a Phase 1 Single …See details»
Palisade Bio Announces Exercise of Previously Issued Warrants for …
Carlsbad, CA, Jan. 30, 2024 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade” or the “Company”), a biopharmaceutical company focused on developing novel …See details»
Palisade Bio | Advancing Next-Generation Precision Therapies
Sep 6, 2023 –Lead program, GT-2108 for the treatment of moderate-to-severe ulcerative colitis advancing toward completion of I ND-enabling studies with IND filing expected by Q3 2024See details»
Palisade Bio Announces Successful Completion of First GMP …
Jul 11, 2024 The GMP manufacturing was conducted in partnership with Eurofins, a contract development and manufacturing organization. This partnership included process development …See details»
Palisade Bio Successfully Demonstrates Bioactivation of PALI-2108 …
Apr 16, 2024 Company continues advancing ongoing development of targeted therapies for ulcerative colitis (UC) Carlsbad, CA, April 16, 2024 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. …See details»
Palisade Bio’s Lead Product Candidate, PALI-2108 Demonstrates …
May 1, 2024 Company on track to commence Phase 1 human clinical study of PALI-2108 for the treatment of Ulcerative Colitis (UC) before year end. Carlsbad, CA, May 01, 2024 — Palisade …See details»
Palisade Bio Announces Topline Results from U.S. Phase 2 PROFILE …
Aug 9, 2023 – Study did not achieve primary efficacy endpoint of reducing adhesions in LB1148 treated patients compared to placebo treated patients post bowel resection surgery Carlsbad, …See details»
Palisade Bio Announces Positive Data from Two Ex Vivo …
Oct 31, 2024 Targeted, better-tolerated oral PDE4 inhibitors are an unmet need in inflammatory bowel disease (IBD) PALI-2108 demonstrates in ex vivo studies; targeted activation and …See details»